Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

Drugs

Volumn 63, Issue 8, 2003, Pages 803-843

  Plosker, Greg L ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Chronic lymphocytic leukaemia; Dosage and administration; Lymphoid malignancies; Non Hodgkin's lymphoma; Pharmacodynamics; Pharmacokinetics; Rituximab; Therapeutic use; Tolerability

Indexed keywords

BRONCHODILATING AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; PARACETAMOL; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ANEMIA; ANGIONEUROTIC EDEMA; BLOOD TOXICITY; BRONCHITIS; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CARDIOGENIC SHOCK; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COUGHING; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG CONCENTRATION; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEVER; FLU LIKE SYNDROME; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPOPLASIA; HYPOTENSION; HYPOXIA; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG INFILTRATE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; RESPIRATORY DISTRESS; REVIEW; RHINITIS; SEPSIS; SINUSITIS; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN;

HERPES; HERPES ZOSTER;

EID: 0037251878     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363080-00005     Document Type: Review

References (177)

1. Grillo-López AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 105-12
2. MabThera: Summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/# [Accessed 2002 Sep 25]
3. Mosby's drug consult update 4: rituximab [online]. Available from URL: http://www.mosbysgenrx.com [Accessed 2002 Sep 20]
4. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88
5. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33
6. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346: 235-42
7. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002 Jun; 13 (6): 928-43
8. Harrison's Online; Chapter 112: Malignancies of lymphoid cells [online]. Available from URL: http://www.harrisonsonline.com [Accessed 2002 Nov 22]
9. National Cancer Institute. Adult non-Hodgkin's lymphoma (PDQ®): treatment [online]. Available from URL: http://www.cancer.gov/cancerinfo/pdq/treatment/adult-non-hodgkins/ healthprofessional/ [Accessed 2002 Sep 20]
10. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin 2001; 51: 15-36
11. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14): 987-94
12. Cheson BD. CHOP plus rituximab balancing facts and opinion. N Engl J Med 2002 Jan 24; 346 (4): 280-2
13. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 36-40
14. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 30-5
15. National Cancer Institute. Chronic lymphocytic leukemia (PDQ®): treatment [online]. Available from URL: http://www.cancer.gov/cancer_information/ [Accessed 2002 Sep 20]
16. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12 (3): 177-86
17. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435-45
18. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B- cell lymphoma. Blood 1994; 84: 2457-66
19. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-33
20. Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67: 134-40
21. Petryk M, Grossbard ML. Rituximab therapy of B-cell neoplasms. Clin Lymphoma 2000 Dec; 1 (3): 186-94; discussion 195-6
22. Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259-63
23. Ghielmini M, Schmitz S-FH, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial [abstract no. 604] [online]. Available from URL: http://www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
24. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Brit J Haematology 2000; 109: 81-8
25. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999; 26 (5): 88-96
26. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002 Feb 1; 99 (3): 856-62
27. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001 Jan 1; 97: 101-6
28. Gazzano-Santoro H, Ralph P, Ryskamp TC, et al. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 1997; 202: 163-71
29. Harjunpää A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51 (6): 634-41
30. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000 Jun 15; 95 (12): 3900-8
31. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204: 55-63
32. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001 Mar; 7: 709-23
33. Ghetie M-A, Bright H, Vitetta ES. Homodimers but not monmers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001 Mar 1; 97 (5): 1392-8
34. Taji H, Kagami Y, Okada Y, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89: 748-56
35. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48 (12): 673-83
36. Mathas S, Rickers A, Bommert K, et al. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000 Dec 15; 60: 7170-6
37. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000 Apr; 26 (2): 133-43
38. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002 Jan; 87 (1): 33-43
39. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 2-9
40. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001 Dec 1; 98 (12): 3383-9
41. Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002 Feb 15; 99: 1314-9
42. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase- independent mechanism involving the generation of reactive oxygen species. Blood 2001 Nov 1; 98 (9): 2771-7
43. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002 Feb 1; 99: 1038-43
44. Van Der Kolk LE, Evers LM, Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002 Sep; 16 (9): 1735-44
45. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961-6
46. Alas S, Ng C-P, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002 Mar; 8 (3): 836-45
47. Venugopal P, Sivaraman S, Huang XK, et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24: 411-5
48. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood 1997; 90: 2188-95
49. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74
50. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001
51. Piro LD, White CA, Grillo-López AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10 (6): 655-61
52. Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) [abstract no. 1142]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando, Florida, 286a
53. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non- Hodgkin's lymphoma? [letter]. Ann Oncol 2000; 11: 374-5
54. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 May 15; 20 (10): 2453-63
55. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-803
56. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002 Aug 1; 20 (15): 3262-9
57. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002 Jun 15; 99 (12): 4336-42
58. Hainsworth JD, Litchy S, Burris III HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20 (20): 4261-7
59. Garcia-Conde J, Conde E, Sierra J, et al. Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low grade B-cell lymphoma after relapse: results after 6 months of follow-up. 36th Proc Am Soc Clin Oncol 2000 May 20; 19: 26
60. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17 (1): 268-76
61. Hainsworth JD, Burris HA, Yardley DA, et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a Minnie Pearl Cancer Research Network phase II trial. 38th Annual Meeting of the American Society of Clinical Oncology 2002 May 18; 21 (Pt 1): 268
62. Conconi A, Thiéblemont C, Martinelli G, et al. Activity of rituximab in extranodal marginal zone lymphomas (MALT-type) [abstract no. 3354]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7-11; Orlando, Florida
63. Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851-7
64. Hiddemann W, Forstpointner R, Fiedler F, et al. The addition of rituximab to combination chemotherapy with fludarabine cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL). Results of a prospective randomized comparison of the German Low Grade Study Group (GLSG) [abstract no. 3507]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7-11; Orlando, Florida
65. Kimby E, Geisler C, Hagberg H, et al. Rituximab (Mabthera®) as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study M 39035 [abstract no. 2479]. Blood 2000 Nov 16; 96 (Pt 1): 577a
66. Rubio-Borja MEE, Tripp FJ, Baez E, et al. CNOP vs CNOP-R vs rituximab monotherapy as first-line therapy for indolent non-Hodgkin lymphoma (I NHL). A preliminary report from the Mexican Multicentric Hematology Study Group [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
67. Cortes-Funes H, de la Serna J, Flores E, et al. Rituximab immunotherapy in patients with relapsed follicular or low grade B-cell non-Hodgkin's lymphoma; results after a six month follow-up cut- off. 36th Proc Am Soc Clin Oncol 2000; 19: 31
68. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000 Sep; 18: 3135-43
69. FeuringBuske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000 Sep; 79: 493-500
70. Investigational data from randomized study of extended therapy with Rituxan demonstrates potential to delay disease progression in patients with indolent NHL [online]. Available from URL: http://www.ihmf.org/journal/ [Accessed 2002 Jun 25]
71. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): a phase II trial in the North Central Cancer Treatment Group (NCCTG) [online]. Available from URL: www.hematology.org/meetting/abstracts.cfm [Accessed 2002 Dec 10]
72. McLaughlin P, Hagemeister FB, Grillo-López AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26 (5): 79-87
73. Cheson B, Horning S, Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17 (4): 1244-53
74. Grillo-López AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: Importance of 'normal' lymph node size and correlations with response rates. Ann Oncol 2000; 11 (4): 399-408
75. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002 Apr; 29 (2 Suppl. 6): 18-22
76. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002 Jan 1; 99: 67-74
77. Van der Kolk LE, Grillo-López AJ, Baars JW, et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy [abstract no. 3167]. Blood 2000; 96 Suppl. 1: 732a
78. Davis TA, Maloney DG, Grillo-López AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000; 6: 2644-52
79. Domingo-Doménech E, González-Barca E, Estany C, et al. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas [abstract]. Haematologica 2002 Nov; 87 (11): 1229
80. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002 Jun; 117 (4): 828-34
81. Sacchi S, Federico M, Vitolo U, et al. Phase II study of rituximab after priming with IFN in patients with relapsed LG/F B-cell lymphoma [abstract no. 399]. Blood 1999 Nov 15; 94 Suppl. 1 (10 Pt 1)
82. Sacchi S, Tucci A, Merli F, et al. Phase II study with fludarabine and cyclophosphamide plus rituximab (FC+R) in relapsed follicular lymphoma patients [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
83. Cohen A, Polliack A, Ben-Bassat I, et al. Results of a phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): The Israel Cooperative Lymphoma Group [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
84. Czuczman M, Grillo-López AJ, White CA, et al. Progression free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy [abstract no. 2519]. Blood 2001 Nov 16; 98 (11 Pt 1): 601a
85. Emmanouilides C, Rosen P, Telatar M, et al. Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1 (2): 146-51
86. Gregory SA, Venugopal P, Adler S, et al. Combined fludarabine, mitoxantrone, and rituximab achieves a high initial response as initial treatment for advanced low grade non-Hodgkin's lymphoma (LGNHL) [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
87. Jäeger G, Neumeister P, Brezinschek R, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002; 69: 21-6
88. Martinelli G, Laszlo D, Mancuso P, et al. Rituximab plus chlorambucil in low-grade non Hodgkin's lymphomas (NHL): clinical results of a phase II study [online]. Available from URL: www.hematology.org/meetings/cfm [Accessed 2002 Dec 10]
89. Vitolo U, Boccomini C, Ladett M, et al. High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemoimmunotherapy FND + rituximab [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
90. Brugger W, Hirsch J, Repp R, et al. Treatment of follicular and mantle cell non-Hodgkin's lymphoma with anti-CD20 antibody Rituximab after high-dose chemotherapy and autologous CD34+ selected blood stem cell transplantation [abstract no. 273]. Onkologie 2001 Sep; 24 Suppl. 6: 72
91. Ladetto M, Ricca I, Benedetti F, et al. Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: an interim analysis [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
92. Buckstein RJ, Imrie KR, Spaner D, et al. Autologous stem cell transplants combined with rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions [abstract no. 2846]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7-11; Orlando, Florida
93. Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83 (12): 3800-7
94. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81 (12): 3449-57
95. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001 Jan; 12: 109-14
96. Berinstein NL, Buckstein R, Imrie K, et al. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 2002 Feb; 29 Suppl. 1: S14-7
97. Brugger W, Hirsch J, Repp R, et al. Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: a multicenter phase II study [abstract no. 2532]. 44th Annual Conference of the American Society of Hematology; 2002 Dec 6-10; Philadelphia
98. Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy. Blood 2001 Nov 16; 98 (Pt 1): 346
99. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicentre phase II study. Blood 1998; 92 (6): 1927-32
100. Winkler U, Schulz HR, Klein TO, et al. Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan¢): evaluation of safety and response [abstract no. 4419]. Blood 1999 Nov 15; 94 Suppl. 1 (10 Pt 2): 270b
101. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001 Jan 15; 19: 389-97
102. Wilson WH, Gutierrez M, O'Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002 Feb; 29 Suppl. 2: 41-7
103. Younes A, McLaughlin P, Hagenmeister FB, et al. High response rate and complete remission rate achieved by adding rituximab to taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma [abstract no. 1456]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7-11; Orlando, FL
104. Zoz M, Krämer A, Krasniqi F, et al. Taxane, cyclophosphamide plus rituximab in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Onkologie 2001 Sep; 24 Suppl. 6: 217
105. Venugopal P, Gregory SA, Wooldridge J, et al. Phase II study of rituximab in combination with CHOP chemotherapy and GMCSF in patients with previously untreated aggressive non-Hodgkin's lymphoma [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
106. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-24
107. Ghielmini M, Schmitz S-FH, Bürki K, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol 2000; 11: S123-6
108. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002 Mar 1; 20: 1288-94
109. Hiddemann W, Unterhalt M, Dreyling M, et al. The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG) [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
110. Tsai DE, Moore HCF, Hardy CL, et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24 (5): 521-6
111. Pan D, Moskowitz CH, Zelenetz AD, et al. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J 2002; 8 (5): 371-6
112. Garcia-Sanz R, Vargas Montero M., Gonzalez Diaz M, et al. Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. Haematologica 1998 Mar; 83 (3): 209-16
113. Levine AM, Espina BM, Mohrbacher A, et al. Fludarabine, mitoxantrone and Rituxan: an effective regimen for the treatment of mantle cell lymphoma [online]. Available from URL: www. hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
114. Rodriguez MA, Sarris A, East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): a safe and effective combination [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
115. Vose JM, Link BK, Grossbard ML, et al. Long term follow-up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL) [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
116. Horwitz SM, Breslin S, Negrin RS, et al. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma (NHL): preliminary results of a phase 1-II trial. 36th Proc Am Soc Clin Oncol 2000 May 20; 19: 51
117. Horwitz SM, Negrin RS, Stockerl-Goldstein KE, et al. Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas [abstract no. 3578]. The American Society of Hematology 43rd Annual Meeting; 2001 Dec 7-11; Orlando, Florida
118. Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 56-69
119. Cortelazzo S, Rambaldi A, Rossi A, et al. High-dose sequential (HDS) chemotherapy with high-dose ARA-C and rituximab prolongs the survival of patients with resistant/relapsed B-cell non-Hodgkin's lymphoma [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
120. Olivieri A, Lucesole M, Spitaleri L, et al. Salvage therapy with rituximab plus GM-CSF and CHOP is effective in lymphoma patients relapsed after auto PBSC transplant. Interim analysis from open prospective study in 25 patients [abstract P449]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S92
121. Cheson BD, Bennett MM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7
122. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003 Jan 1; 101 (1): 6-14
123. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001 Sep 1; 98: 1326-31
124. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001 Apr 15; 19: 2153-64
125. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001 Apr 15; 19: 2165-70
126. Itälä M, Geisler Ch, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69: 129-34
127. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002 Nov 1; 100 (9): 3115-20
128. Herold M, Schulze A, Härtwig K, et al. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab. Ann Hematol 2000 Jun; 79: 332-5
129. Winkler J, Rech J, Valerius T, et al. Treatment with rituximab in a patient with a high tumor cell load in an advanced-stage B-CLL without tumor lysis syndrome. Onkologie 1999 Aug; 22 Suppl. 1: 61
130. Poretta TA, Devereux L, Grana G, et al. Rituximab, cyclophosphamide, and dexamethasone provide hematologic and immunologic response in patients with relapsed chronic lymphocytic leukemia and associated autoimmune activity [abstract no. 2650]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco, CA20
131. Iannitto E, Ammatuna E, Marino C, et al. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody [letter]. Blood 2002 Feb 1; 99 (3): 1096-7
132. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia [abstract no. 4723]. Blood 2001 Nov 16; 98 (11 Pt 2): 248
133. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999 Oct 1; 94: 2217-24
134. Greil R, Steurer M, Egle A, et al. Stepping up treatment with Rituxan® (rituximab, Mabthera®) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy [abstract no. 4903]. Blood 2001 Nov 16; 98 (Pt 2): 289-90
135. Nabhan C, Tallman MS, Riley MB, et al. Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2001 Nov 16; 98 (Pt 1): 365
136. Keating MJ, O'Brien S, Cortes J, et al. Fludarabine and cyclophosphamide combined with Rituxan (FCR) is a potent cytoreductive regimen as initial therapy of chronic lymphocytic leukemia [abstract no. 21]. 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans, LA, 8a
137. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76-82
138. Lanum SA, Lynch Jr ML, Johnson ML. Rituximab use at Shands-University of Florida [abstract no. 139]. 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans
139. Silling G, Scheffold C, Nolte A, et al. Allogeneic stem cell transplantation with dose-reduced conditioning for chronic lymphocytic leukemia (CLL): role of consolidation with rituximab. Bone Marrow Transplant
140. Bole J, Li Y, Tsukada N, et al. Combined rituximab and high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
141. Hegde U, Whilte T, Stetler-Stevenson M, et al. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
142. Odaimi M, Rubin A, Ahern K, et al. Interim results of a phase II trial of therapy with cyclophosphamide/pentostatin/rituximab for indolent NHL and CLL [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
143. Tsimberidou AM, Thomas DA, Faderl S, et al. Alternating cyclophosphamide, vincristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hCVXD) with methotrexate (MTX), and Ara-C (A) regimen plus rituximab and GM-CSF in patients with refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome (RS). Blood 2001 Nov 16; 98 (11 Pt 2): 294b
144. Weide R, Heymanns J, Pandorf A, et al. Bendamustine/mitoxantrone/rituximab (BMR): a new effective treatment for refractory or relapsed indolent lymphomas [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
145. Emmerich B, Huhn D, Peschel C, et al. Treatment of chronic lymphocytic leukemia with the anti-CD20 antibody rituximab. Blood 1999 Nov 15; 94 (Suppl 1, Pt 2): 309
146. Schilling C, Huhn D, Schriever F, et al. Rituximab in far-advanced B-CLL: a multi-centre trial with conventional dosing. Hematol J 2000 Jun: 1 Suppl. 1: 93
147. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) [abstract no. 1530]. Blood 2001 Nov 16; 98 (Pt 1): 363
148. Thomas DA, O'Brien S, Giles FJ, et al. Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL) [abstract no. 1533]. Blood 2001 Nov 16; 98 (Pt 1): 364
149. Faderl S, Thomas DA, O'Brien S, et al. Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies - an update of the M.D. Anderson experience [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
150. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies [online]. Available from URL: http://www.blodjournal.org [Accessed 2003 Feb 5]
151. Weiss MA, Lamanna N, Gencareli A, et al. Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab improves the quality of response in patients with previously untreated chronic lymphocytic leukemia [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
152. Garcia Manero G, O'Brien S, Cortes J, et al. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia. Blood 2001 Nov 16; 98 (Pt 1): 633
153. Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001 Nov 16; 98 (Pt 1): 771
154. Keating M, Manshouri T, O'Brien S, et al. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia (CLL) [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
155. Polliack A, Cohen Y, Daas N, et al. Fludarabine (FLU)-containing regimen and rituximab (RI) as primary therapy with curative intent for younger patients with progressive and advanced B- CLL: high rate of initial response including molecular remissions. Blood 2001 Nov 16; 98 (Pt 1): 364
156. Drapkin R, Di Bella NJ, Cuasay LC, et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated or untreated chronic lymphocytic leukemia [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
157. Mauro FR, Gentile M, Alimena G, et al. Postremissional rituximab administration for the treatment of poor prognosis chronic lymphocytic leukemia (CLL) patients [online]. Available from URL: www.hematology.org/meeting/abstracts.cfm [Accessed 2002 Dec 10]
158. Trneny M, Salkova J, Karban J, et al. Combined therapeutic morality with rituximab, fludarabin and cyclophosphamide followed by high dose therapy with autologous stem cell transplantation (ASCT) leads to excellent response rate and high probability of molecular remission in chronic lymphocytic leukemia (CLL) patients [abstract no. 3176]. 44th Annual Meeting of the American Society of Hematology; 2002 Dec 6-10; Philadelphia, PA
159. Kunkel L, Wong A, Maneatis T, et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol 2000 Dec; 27 Suppl. 12: 53-61
160. Kunzmann V, Ruediger T, Hallek M, et al. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001 Sep 15; 98: 1991-2
161. Sivakumaran M. Rituximab-induced tumor cell agglutination [letter]. Blood 2002 Oct 1; 100 (7): 2672
162. Burchmore MJ, Dowden S. One year cost of treatment of rituximab compared to fludarabine for relapsed or refractory, low-grade or follicular non-Hodgkin's lymphoma [abstract no. 91]. 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, 25
163. Hieke K, Sweetenham J, Omnes LF, et al. International assessment of costs of drug delivery associated with CHOP, COP, fludarabine and rituximab [abstract no. PP26 plus poster]. Eur J Cancer 2000 Aug; 36 Suppl. 3: 17
164. Omnes LF, Foutel V, Haioun C, et al. Comparative economic analysis of the treatment of relapsed low grade B-cell non-Hodgkin's lymphoma in France using CHOP, fludarabine or rituximab [abstract no. 420]. Blood 1999 Nov 15; 94 Suppl. 1 (10 Pt 1): 96
165. Scott SD, Hetherington N, Link BK. The cost-effectiveness of treatment of rituximab compared to fludarabine for relapsed or refractory low-grade/follicular NHL [abstract no. 1774]. 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans, LA, 452
166. Cattaneo MJ, Nichol MB. Cost-effectiveness of rituximab in relapsed, refractory, low-grade non- Hodgkin's lymphoma [abstract no. PCN7, plus poster]. Value Health 2000; 3 (2): 130-1
167. Conde E, Sañudo E, Garcia-Conde J, et al. Cost minimisation analysis of rituximab, CHOP and fludarabine in the treatment of relapsed or chemotherapy-refractory follicular lymphoma [abstract; in Spanish]. 4th National Congress of the FESEO; 2000 Oct 4-6; Corunna, Spain
168. Sweetenham J, Hieke K, Kerrigan M, et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Br J Haematol 1999; 106 (1): 47-54
169. Coiffier B, Best JH, Omnes LF, et al. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma [abstract no. 3586]. Blood 2001 Nov 16; 98: 864a
170. Hamblin T, Best JH, Hornberger J, et al. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma [abstract no. 170]. J. Haematol. 2002 May; 117 Suppl. 1: 59-60
171. Best J, Hornberger J, Omnes LF, et al. Cost-effectiveness of rituximab in diffuse large B-cell lymphoma [abstract no. PCN13]. Value Health 2002; 5 (3): 198-9
172. Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology 1998 May; 12 (5): 697-714
173. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econom 2002; 3: 166-72
174. Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use. Haematologica 2002; 87: 719-29
175. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17 (3): 791-5
176. Nabhan C, Rosen ST. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 75-80
177. Keating MJ, O'Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 70-4